News Articles

Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment

March 19, 2020

ATLANTA and MIAMI, March 19, 2020 /PRNewswire/ — Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, today announced a collaboration to rapidly advance DRIVE’s EIDD-2801, a promising oral COVID-19 treatment, into human testing. This collaboration combines Ridgeback’s unique experience…

Read More

SEC Regulatory Changes Provide Small Biotech Companies Relief from Burdensome Requirements

March 12, 2020

Washington, DC (March 12, 2020) – The Securities and Exchange Commission (SEC) has adopted regulatory changes to provide small public companies with a temporary exemption from Sarbanes-Oxley 404(b) compliance. 404(b) requires public companies to report on the internal controls they have in place over their financial reporting. While well-intended, this regulatory requirement has proven to reduce market…

Read More

Medline Industries, Inc. to Create 150 Jobs, Invest $70 Million in Bryan County

March 11, 2020

Atlanta, GA – Governor Brian P. Kemp today announced that Bryan County will be home to Georgia’s newest Medline Industries, Inc. location in the state. Medline, the largest privately held manufacturer and distributor of medical supplies, will invest over $70 million to build a new distribution center in Richmond Hill that will create 150 new jobs…

Read More

Coronavirus: Takeda Pursues Plasma-Derived Treatment; Alnylam and Vir Eye siRNA Therapy

March 4, 2020

Two big-name biopharmas—Takeda Pharmaceutical and Alnylam Pharmaceuticals—today separately entered the scramble to develop new treatments for SARS-CoV-2 infection, the virus identified as the cause of the global COVID-19 outbreak—adding to the 35 coronavirus treatments in development that were identified by GEN this week. Takeda said it has begun development of TAK-888, an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) designed to…

Read More

Boehringer links up with Trutino for cancer R&D

March 2, 2020

Boehringer Ingelheim has entered a research collaboration and licensing agreement with biopharma company Trutino Bioscience, with the aim of developing new cancer immunology compounds.  The agreement will leverage Trutino’s On-Demand-Cytokine (ODC) platform, which is designed to mask the activity of cytokines until they reach the targeted tumour site and become fully activated. This means the…

Read More

Top Emory biotech expert on coronavirus: ‘Efforts should be made to keep business on track’

February 26, 2020

A top biotech expert at Emory University says U.S. businesses should think twice before shutting down facilities over coronavirus fears.  “Certainly I think efforts should be made to keep business on track. I don’t think wholesale shutdowns in the absence of reasoned probability of spreading the disease is advisable,” said George Painter in a Feb. 25 interview…

Read More